RHJA
EOLS icon

Rice Hall James & Associates’s Evolus EOLS Stock Holding History

Rice Hall James & Associates’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.95M Buy
1,289,888
+35,069
+3% +$207K 0.44% 65
2026
Q1 		$5.16M Buy
1,254,819
+101,375
+9% +$491K 0.29% 82
2025
Q4 		$7.67M Sell
1,153,444
-15,442
-1% -$105K 0.42% 62
2025
Q3 		$7.18M Buy
1,168,886
+172,846
+17% +$1.35M 0.39% 68
2025
Q2 		$9.17M Buy
996,040
+74,646
+8% +$764K 0.49% 52
2025
Q1 		$11.1M Sell
921,394
-26,887
-3% -$352K 0.65% 45
2024
Q4 		$10.5M Buy
948,281
+43,381
+5% +$610K 0.58% 51
2024
Q3 		$14.7M Buy
904,900
+53,605
+6% +$749K 0.79% 36
2024
Q2 		$9.24M Sell
851,295
-29,449
-3% -$362K 0.55% 53
2024
Q1 		$12.3M Sell
880,744
-25,451
-3% -$331K 0.7% 39
2023
Q4 		$9.54M Sell
906,195
-198,964
-18% -$1.78M 0.55% 47
2023
Q3 		$10.1M Buy
1,105,159
+421,890
+62% +$3.78M 0.64% 44
2023
Q2 		$4.97M Buy
683,269
+522,675
+325% +$4.51M 0.28% 86
2023
Q1 		$1.36M Buy
+160,594
New +$1.45M 0.08% 222

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Rice Hall James & Associates's EOLS Position: Q2 2026 in Review

Rice Hall James & Associates increased its Evolus (EOLS) stake by 2.8% in Q2 2026, buying an estimated $207K and bringing the position to 1,289,888 shares worth $8.95M. The position accounts for 0.44% of the portfolio, ranked #65.

Rice Hall James & Associates first reported a position in EOLS in Q1 2023 and has held it in 14 quarters since. The position peaked at $14.7M in Q3 2024. 158 funds tracked by Wall St. Rank hold EOLS as of Q2 2026.

  • Rice Hall James & Associates held 1,289,888 shares of Evolus worth $8.95M as of Q2 2026.
  • Rice Hall James & Associates bought 35,069 Evolus shares in Q2 2026, an estimated $207K.
  • Evolus made up 0.44% of Rice Hall James & Associates's portfolio in Q2 2026, its #65 holding.
  • Rice Hall James & Associates first reported a position in Evolus in Q1 2023 and has held it in 14 quarters since.
  • Rice Hall James & Associates's Evolus position peaked at $14.7M in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Evolus as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.